Cui Q, Huang C, Liu J, Zhang J
J Med Chem. 2023; 66(24):16515-16545.
PMID: 38092421
PMC: 11588358.
DOI: 10.1021/acs.jmedchem.3c01130.
Alatise K, Gardner S, Alexander-Bryant A
Cancers (Basel). 2022; 14(24).
PMID: 36551731
PMC: 9777152.
DOI: 10.3390/cancers14246246.
Han T, Sha H, Ji J, Li Y, Wu D, Lin H
Sci Rep. 2021; 11(1):2283.
PMID: 33504817
PMC: 7840972.
DOI: 10.1038/s41598-021-81563-3.
Faccion R, Bernardo P, de Lopes G, Soares Bastos L, Teixeira C, de Oliveira J
Cell Oncol (Dordr). 2018; 41(2):141-157.
PMID: 29374392
DOI: 10.1007/s13402-017-0361-5.
Conde M, Michen S, Wiedemuth R, Klink B, Schrock E, Schackert G
BMC Cancer. 2017; 17(1):889.
PMID: 29282022
PMC: 5745881.
DOI: 10.1186/s12885-017-3932-y.
Major apoptotic mechanisms and genes involved in apoptosis.
Kiraz Y, Adan A, Yandim M, Baran Y
Tumour Biol. 2016; 37(7):8471-86.
PMID: 27059734
DOI: 10.1007/s13277-016-5035-9.
Localization and upregulation of survivin in cancer health disparities: a clinical perspective.
Khan S, Ferguson Bennit H, Valenzuela M, Turay D, Diaz Osterman C, Moyron R
Biologics. 2015; 9:57-67.
PMID: 26185415
PMC: 4501680.
DOI: 10.2147/BTT.S83864.
Survivin as a preferential target for cancer therapy.
Mobahat M, Narendran A, Riabowol K
Int J Mol Sci. 2014; 15(2):2494-516.
PMID: 24531137
PMC: 3958864.
DOI: 10.3390/ijms15022494.
Targeting caspases in cancer therapeutics.
Hensley P, Mishra M, Kyprianou N
Biol Chem. 2013; 394(7):831-43.
PMID: 23509217
PMC: 3721733.
DOI: 10.1515/hsz-2013-0128.
The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer.
Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H
PLoS One. 2013; 8(2):e55710.
PMID: 23405201
PMC: 3565976.
DOI: 10.1371/journal.pone.0055710.
Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells.
Chen X, Yang S, Li Z, Lu H, Kang M, Lin T
Mol Med Rep. 2012; 5(4):917-22.
PMID: 22246162
PMC: 3493107.
DOI: 10.3892/mmr.2012.755.
Survivin in solid tumors: rationale for development of inhibitors.
Church D, Talbot D
Curr Oncol Rep. 2012; 14(2):120-8.
PMID: 22234703
DOI: 10.1007/s11912-012-0215-2.
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Kelly R, Lopez-Chavez A, Citrin D, Janik J, Morris J
Mol Cancer. 2011; 10:35.
PMID: 21470426
PMC: 3083377.
DOI: 10.1186/1476-4598-10-35.
Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas.
Adamkov M, Halasova E, Rajcani J, Bencat M, Vybohova D, Rybarova S
Med Sci Monit. 2011; 17(3):BR74-80.
PMID: 21358596
PMC: 3524735.
DOI: 10.12659/msm.881442.
Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer.
Zohny S, El-Shinawi M
Med Oncol. 2010; 28 Suppl 1:S108-14.
PMID: 20978950
DOI: 10.1007/s12032-010-9724-8.
Poriferan survivin exhibits a conserved regulatory role in the interconnected pathways of cell cycle and apoptosis.
Luthringer B, Isbert S, Muller W, Zilberberg C, Thakur N, Worheide G
Cell Death Differ. 2010; 18(2):201-13.
PMID: 20651742
PMC: 3131884.
DOI: 10.1038/cdd.2010.87.
Signals of apoptotic pathways in several types of meningioma.
Sabbatini M, Comi C, Chiocchetti A, Piffanelli V, Car P, Dianzani U
Pathol Oncol Res. 2010; 17(1):51-9.
PMID: 20524098
DOI: 10.1007/s12253-010-9279-1.
Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2.
Rivera Guzman J, Fukuda S, Pelus L
Gene Ther Mol Biol. 2011; 13B:264-273.
PMID: 20428502
PMC: 2859835.
Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line.
Yue Z, Carvalho A, Xu Z, Yuan X, Cardinale S, Ribeiro S
J Cell Biol. 2008; 183(2):279-96.
PMID: 18936249
PMC: 2568024.
DOI: 10.1083/jcb.200806118.
Chemically synthesized human survivin does not inhibit caspase-3.
Li C, Wu Z, Liu M, Pazgier M, Lu W
Protein Sci. 2008; 17(9):1624-9.
PMID: 18539906
PMC: 2525533.
DOI: 10.1110/ps.036145.108.
